Clinical Consequences for Individuals Treated with Tocilizumab for Serious COVID-19 Infection

Autor: Al Shaimaa Ibrahim Rabie, Hager Salah, Amira S. A. Said, Ahmed Hassan Shaaban, Lamya Mohamed Abdou, Doaa Mahmoud Khalil, Zelal Kharaba, Hala Afifi, Mahmoud R. Sofy, Eman M. I. Youssef, Eman S. M. Bayoumy, Raghda R. S. Hussein
Jazyk: angličtina
Rok vydání: 2023
Předmět:
Zdroj: Healthcare
Volume 11
Issue 4
Pages: 607
ISSN: 2227-9032
DOI: 10.3390/healthcare11040607
Popis: There seem to currently be no therapeutic medications found for the severe coronavirus infection in 2019 (COVID-19). In light of this, it has been hypothesized that the immunomodulatory treatment known as tocilizumab can lessen the inflammatory response that occurs in the respiratory system, speed up the process of clinical benefit, lower the risk of death, and avert the need for ventilators. This randomized controlled trial (RCT) studied patients with a proven infection of SARS-CoV-2 and hyperinflammatory reactions. The inclusion criteria included fever (body temperature > 38 °C), pulmonary infiltrates, or supplemental oxygen. The patients received either conventional treatment with one dose of either tocilizumab (8 mg per kilogram of body weight) or conventional treatment only. The subjects were randomized to receive either treatment with a 1:1 ratio. A time-to-event test was conducted to determine the time to intubation or death. There was an insignificant difference between the investigated groups regarding the time to death, time to mechanical ventilation, and percentage of deaths. The conventional group’s median (IQR) hospital length of stay was 4 (3–6) days, whereas the tocilizumab therapy group was 7 (4.75–10) days. There was a substantial difference in the mechanical ventilation rates in both groups, which were 17 (34%) and 28 (56%), respectively. In hospitalized patients with severe illness and COVID-19, tocilizumab was ineffective in preventing intubation or death. Trials must be larger, however, in order to exclude the potential benefits or harms.
Databáze: OpenAIRE
Externí odkaz: